Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
proton pump inhibitor + colloidal bismuth pectin
- Development stage
- Unknown
- Lead developer
- Shanxi Xinbaoyuan Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A quadruple therapy regimen combining a proton pump inhibitor with colloidal bismuth pectin and two antibiotics (typically amoxicillin and tetracycline or clarithromycin). This combination is primarily used for Helicobacter pylori (H. pylori) eradication. Colloidal bismuth pectin is a high molecular weight bismuth agent that has a strong affinity for damaged epithelial cells in the gastrointestinal mucosa. When combined with a PPI and antibiotics, it provides high efficacy in H. pylori treatment.
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on proton pump inhibitor + colloidal bismuth pectin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on proton pump inhibitor + colloidal bismuth pectin.